Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdvanTIG-306: Ociperlimab + Tislelizumab + Chemo in First-Line NSCLC
NCT05791097Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- IgG Antibodies, Immune Checkpoint Inhibitors
01
Overview
A Phase 3 trial of ociperlimab in non-small cell lung cancer (NSCLC), sponsored by Novartis. Planned start Jul 2023; status: withdrawn.
02
Drugs
ociperlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05791097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05791097.